| 研究課題/領域番号 |
21K14812
|
|---|
| 研究種目 |
若手研究
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
小区分38050:食品科学関連
|
|---|
| 研究機関 | 北海道大学 |
|---|
研究代表者 |
|
|---|
| 研究期間 (年度) |
2021-04-01 – 2025-03-31
|
| 研究課題ステータス |
交付 (2023年度)
|
| 配分額 *注記 |
4,030千円 (直接経費: 3,100千円、間接経費: 930千円)
2024年度: 780千円 (直接経費: 600千円、間接経費: 180千円)
2023年度: 780千円 (直接経費: 600千円、間接経費: 180千円)
2022年度: 1,170千円 (直接経費: 900千円、間接経費: 270千円)
2021年度: 1,300千円 (直接経費: 1,000千円、間接経費: 300千円)
|
|---|
| キーワード | Hijiki / obesity / Sphingolipid metabolism / lipids / LC/MS / Obesity |
|---|
| 研究開始時の研究の概要 |
(1) Isolate and characterize the chemical constituent of Hijiki responsible for SMS inhibition. (2) Determination of its IC50 and mode of action on the lipid droplet formation by cell-based assay (3) Revealing the in vitro effects by analysis of altered cellular lipid biomarkers by LC-MS (4) Elucidate the in vivo effects by oral administration of the active constituent of
Hijiki using High-fat diet mouse model.
|
| 研究実績の概要 |
We achieved significant progress in our research in the last year. We successfully established the sphingomylein synthase (SMS) monitoring assay method using LC/MS and validated by in-vitro and in-silico studies using a known inhibitor for SMS. Also, the manuscript was prepared and submitted to the international peer-reviewed journal. We successfully identified the compound in Hijiki responsible for SMSs nhibition by mass spectrometry and NMR techniques. The identified compound was confirmed with authentic standard. Further, we investigated the inhibition affinity of active compounds with SMS enzymes by docking studies. The summary of results including isolation characterization and SMS assay results are under preparation for a possible manuscript while further studies are in progress.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
Due to the characterization of the active component in Hijiki, there is slight delay in the progress, however it is going rather smoothly now as we successfully characterized the active component of hijiki responsible for SMS inhibition.
|
| 今後の研究の推進方策 |
We have now isolated the active component of Hijiki with complete characterization by spectroscopic and spectrometry techniques. Our future goal is to test this active compound in in-vitro and in-vivo system. We will first perform the in-vitro activity of the Hijiki derived SMS inhibitor using fatty liver disease cell model by LC/MS and fluorescence microscopy techniques. The inhibition at cellular levels will be confirmed by measuring sphingomylein lipid in the C3A cells. Based on the in-vitro results, the in-vivo studies will be conducted as planned in the proposal and an overall report will be prepared by the end of the fiscal year. Additionally, the manuscript will be prepared to submit to an international journal and also results will be presented at a domestic conference.
|
